First pharmacokinetic and safety study in humans of the novel lipid antiviral conjugate CMX001, a broad-spectrum oral drug active against double-stranded DNA viruses. - Wikidata - awgldk - TriplyDB

First pharmacokinetic and safety study in humans of the novel lipid antiviral conjugate CMX001, a broad-spectrum oral drug active against double-stranded DNA viruses.

First pharmacokinetic and safety study in humans of the novel lipid antiviral conjugate CMX001, a broad-spectrum oral drug active against double-stranded DNA viruses.

http://www.wikidata.org/entity/Q35941261

about

Human polyomavirus reactivation: disease pathogenesis and treatment approaches Ebola: a holistic approach is required to achieve effective management and control How I treat resistant cytomegalovirus infection in hematopoietic cell transplantation recipients Advances in antivirals for non-influenza respiratory virus infections.Management of cytomegalovirus infection and disease in liver transplant recipients.Structural Analysis of Monomeric RNA-Dependent Polymerases: Evolutionary and Therapeutic Implications Impact of adenoviral stool load on adenoviremia in pediatric hematopoietic stem cell transplant recipients.Experimental Treatment of Ebola Virus Disease with Brincidofovir.Selection and recombinant phenotyping of a novel CMX001 and cidofovir resistance mutation in human cytomegalovirus.Brincidofovir Is Not a Substrate for the Human Organic Anion Transporter 1: A Mechanistic Explanation for the Lack of Nephrotoxicity Observed in Clinical Studies New immunosuppressive agents in pediatric transplantation.Distribution and effects of amino acid changes in drug-resistant α and β herpesviruses DNA polymerase Orthopoxvirus inhibitors that are active in animal models: an update from 2008 to 2012.Infections following facial composite tissue allotransplantation--single center experience and review of the literature.The human polyomavirus BK (BKPyV): virological background and clinical implications.Diagnosis and treatment of adenovirus infection in immunocompromised patients.Cytomegalovirus infection in liver transplant recipients: updates on clinical management Potential and emerging treatment options for Ebola virus disease.KSHV targeted therapy: an update on inhibitors of viral lytic replication.Human herpesvirus-6 encephalitis after allogeneic hematopoietic cell transplantation: what we do and do not know.Treatment options for progressive multifocal leukoencephalopathy in HIV-infected persons: current status and future directions.Human cytomegalovirus antiviral drug resistance in hematopoietic stem cell transplantation: current state of the art.Treatment of CMV infection after allogeneic hematopoietic stem cell transplantation.45 years after the discovery of human polyomaviruses BK and JC: Time to speed up the understanding of associated diseases and treatment approaches.Cytomegalovirus in hematopoietic stem cell transplant recipients - management of infection.Letermovir Treatment of Human Cytomegalovirus Infection Antiinfective Agent.Human herpesvirus vaccines and future directions.Preliminary Evaluation of the Effect of Investigational Ebola Virus Disease Treatments on Viral Genome Sequences.Administration of Brincidofovir and Convalescent Plasma in a Patient With Ebola Virus Disease.Treatment of alpha and beta herpesvirus infections in solid organ transplant recipients.Case report: Brincidofovir-induced reversible severe acute kidney injury in 2 solid-organ transplant for treatment of cytomegalovirus infection A Case of Adenovirus Viremia in a Pediatric Liver Transplant Recipient With Neutropenia and Lymphopenia: Who and When Should We Treat?Brincidofovir clearance of acyclovir-resistant herpes simplex virus-1 and adenovirus infection after stem cell transplantation.Novel Cytomegalovirus UL54 DNA Polymerase Gene Mutations Selected In Vitro That Confer Brincidofovir Resistance.Development of CMX001 (Brincidofovir) for the treatment of serious diseases or conditions caused by dsDNA viruses.Adenovirus: current epidemiology and emerging approaches to prevention and treatment.Adenovirus in solid organ transplantation.Cytomegalovirus Treatment.The vaccinia virus DNA polymerase structure provides insights into the mode of processivity factor binding.

P2860

Q21285083-393677C2-0C39-4A86-A96C-6FD82D5B5D75 Q26823792-E6A4F2F5-5630-414F-BF77-F402D3732CB7 Q28069489-B93E74FE-DAAF-49FF-8A20-C4B286FC3E61 Q30457132-B3CF678B-2BD4-46E4-B4C8-284D54DB856A Q33845124-DE328576-C8E8-46A2-A585-32743DAF458F Q35784542-F4EFE9EA-5046-4E0F-BBB8-33919CD68701 Q35896270-45610B23-3647-4633-85EC-15C8E56C3A88 Q36127815-6348E3D7-2A79-4F14-8C3A-ABC3E276DA3A Q36969798-5093FC2E-2CCE-43FD-B641-3CE177B8C77D Q37420102-EB00C967-708F-4587-9624-4480FB4D559F Q37446883-ECE8B134-01D1-44FA-93C3-C6ECEC7BC10F Q37523020-30A3D847-3EEB-40EA-9BCB-A246E175216A Q37593480-BEE69FC2-CBCA-4697-813C-AC0F7C7EC3F9 Q38070865-AF6C8938-40B5-471A-9B7A-0808EC02AFDE Q38115582-76C945BB-C11C-4F82-9E74-62ED7EC613F4 Q38145327-3024D4F4-0D0A-448D-8F3D-C7A5FB57F464 Q38242802-0F8A3880-E60B-4EE4-A36F-ED6E4FF390ED Q38270149-FABABD31-6B08-4074-929B-7461C0C02F6D Q38271135-73E85B5B-6DFB-441C-B673-8DFED8DE2D8C Q38444117-BCEE395E-B846-4280-BF6E-76EC99188BB9 Q38665891-5F9D88D0-876D-41F1-8BE9-084FE1F1F391 Q38779846-86A10644-5822-4EBD-B911-1F133B2C1989 Q38797660-094BE76E-D989-480D-B00E-464FEB92D567 Q38801394-151151CB-DBA3-46D3-8D7B-855465899DE9 Q38802522-4A021518-6136-4FD3-B407-A2B9C36F5E77 Q39325580-BCBCE440-1D97-47A0-82C2-F6B3645F787E Q39476453-24D1832C-8B7F-47A6-8129-7D8EDC6BDFE2 Q40092794-AAB66E71-9B5D-4196-B6EB-B5D9F1CCDB86 Q40155280-C53C2FD6-00DE-41E7-9250-D5C63F7C0821 Q40426465-73EA002A-4824-43F6-A64A-B5E729A83E85 Q40446799-089C279D-92E2-4866-80E0-4D082E1AAF95 Q40500504-47F54E25-BD49-4499-B9A2-847C30D4AD93 Q40591596-C1BA812F-9ED8-47A9-9818-B3EF217F656D Q40728808-1A1BB579-6B40-4AAD-B7E9-BEDB14990689 Q42200165-F31F7790-0AB3-4F62-8B2B-FF7648BBA55E Q42211589-1CA4A63B-9B5E-45A8-B50A-8863CE09BB55 Q42272305-C999075A-9CD3-40E1-9C16-5B967EE06961 Q42554715-DBCB852D-9131-4D9D-9655-509E669A442F Q45324928-432D293B-68EB-4553-8D9B-EADAAF27254F

P2860

First pharmacokinetic and safety study in humans of the novel lipid antiviral conjugate CMX001, a broad-spectrum oral drug active against double-stranded DNA viruses.

http://www.wikidata.org/entity/Q35941261

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

First pharmacokinetic and safe ...... t double-stranded DNA viruses.

@ast

First pharmacokinetic and safe ...... t double-stranded DNA viruses.

@en

type

label

First pharmacokinetic and safe ...... t double-stranded DNA viruses.

@ast

First pharmacokinetic and safe ...... t double-stranded DNA viruses.

@en

prefLabel

First pharmacokinetic and safe ...... t double-stranded DNA viruses.

@ast

First pharmacokinetic and safe ...... t double-stranded DNA viruses.

@en

P1433

Q35941261-1D3911FF-4424-4F81-982B-8D5AFD988256

P1476

Q35941261-1898D64E-F1FD-4DB9-A747-F8250AB63892

P2093

Q35941261-1419905D-DC33-49ED-A32D-D835B20CFE53

Q35941261-327025A7-FB31-4949-95DB-18DAC04F2702

Q35941261-5028030D-E0ED-4AA3-AE2C-A5B4C2A29967

Q35941261-7487BB3E-04E3-4CB0-8DED-3EFD18FC8E91

Q35941261-D8740FF8-7A8B-4BAB-9362-849D2AC72587

Q35941261-FD561BC1-0BDA-4398-A879-B22C49519236

P2860

Q35941261-0975D74D-0929-4C92-8306-4297F5B8D423

Q35941261-1040E59E-BA11-4598-9E14-41D360FD8CAA

Q35941261-1636E586-5EAD-4568-81D3-C06D49B826C0

Q35941261-1C5C3632-91FE-4C1C-BAA1-0338C4D4499F

Q35941261-3BED4A81-CB8E-48FC-8846-0812D1433F12

Q35941261-458B57FE-AC7A-4790-8D16-9704CB4E8BB1

Q35941261-5FB2D083-1D42-486F-83D8-C328ACF70229

Q35941261-8E5A2DEF-2E2F-4F52-AF68-068808A9E86E

Q35941261-9F7B6C36-8B83-459D-ACD2-4D30262A08FA

Q35941261-A526D8B2-E7B9-4781-BA91-DF5C9FDEB1EC

P304

Q35941261-3B4E71C9-B5FD-47F0-A4CF-899BCFA4765C

P31

Q35941261-242FCC08-1C98-4006-A993-13670A9BFD00

P356

Q35941261-EE109D59-37F2-46AF-8FA5-D47C71425A2A

P407

Q35941261-295EA377-869F-48BD-A92B-3CE57A0DAF24

P433

Q35941261-884FB3B1-45F9-415D-AC60-F91546E49A98

P478

Q35941261-C585A9E6-EF37-4CD9-9ACC-A074DED3808E

P577

Q35941261-306C9D0E-AD7C-4648-9D91-7C96C09F1318

P5875

Q35941261-44C6D966-D790-49C3-84E1-E49DE7E4F619

P698

Q35941261-003ABD78-B405-498F-A422-2F7F570A28A8

P932

Q35941261-E389C84D-375E-4F7C-94ED-D55149DEDF65

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

First pharmacokinetic and safe ...... t double-stranded DNA viruses.

@en

P2093

Alice Robertson

http://www.w3.org/2001/XMLSchema#string

Bernhard Lampert

http://www.w3.org/2001/XMLSchema#string

George Painter

http://www.w3.org/2001/XMLSchema#string

Lawrence C Trost

http://www.w3.org/2001/XMLSchema#string

Susan Godkin

http://www.w3.org/2001/XMLSchema#string

Wendy Painter

http://www.w3.org/2001/XMLSchema#string

P2860

Viral infections in immunocompromised patients: what's new with respiratory viruses?

Antiviral drug resistance of human cytomegalovirus.

The antiviral nucleotide analogs cidofovir and adefovir are novel substrates for human and rat renal organic anion transporter 1.

Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis.

Progress in understanding cytomegalovirus drug resistance.

Development of CMX001 for the Treatment of Poxvirus Infections.

Clinical pharmacokinetics of cidofovir in human immunodeficiency virus-infected patients

Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections.

Management of CMV infection and disease in transplant patients. 27-29 February 2004.

Alkoxyalkyl prodrugs of acyclic nucleoside phosphonates enhance oral antiviral activity and reduce toxicity: current state of the art.

P304

2726-2734

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.05983-11

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

56

http://www.w3.org/2001/XMLSchema#string

P577

2012-03-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221889181

http://www.w3.org/2001/XMLSchema#string

P698

22391537

http://www.w3.org/2001/XMLSchema#string

P932

3346600

http://www.w3.org/2001/XMLSchema#string